In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Eli Lilly trades 35% above its PERT-weighted fair value of $878, signaling potential overvaluation against key DCF and earnings multiples. High profitability and growth contrast with moderate leverage and elevated Monte Carlo volatility (165%), reflecting significant upside swings but pronounced downside risk (75%). Analyst targets and trading range indicate market expectation of higher valuation variability.